From crippling fatigue to brain fog, CML treatment can affect your body in ways that go beyond the usual side effects.

CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and ...

Priority review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment ...

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

In this video, Jennifer A. Woyach, MD, discusses a phase 3 randomized trial comparing pirtobrutinib to idelalisib or bendamustine plus rituximab for chronic lymphocytic leukemia pretreated with Bruton ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...